Interview with Dr. Laura Niklason, CEO of Humacyte and Rajiv Shukla from Alpha Healthcare SPAC ($AHAC)

Last week I had the pleasure of speaking with Dr. Niklason, Founder & CEO of Humacyte and Rajiv Shukla from Alpha Healthcare ($AHAC) which is the SPAC taking Humacyte public via reverse merger. Rajiv actually took DermTech public a couple years ago through a different SPAC so I’ve been following him for a while.

Humacyte is developing lab-grown human tissues and vessels which could eventually include human organs.

You can learn more about Humacyte on their website at Humacyte.com

Here is information about the SPAC merger [click here]

Here is the Investor Presentation [click here]

I don’t currently have a position in $AHAC (the merger should be complete in the next 4-6 weeks) however this is a stock/company that I’m watching very closely and it’s very possible I take a position in the next 3-6 months as the company applies for FDA approval and then begins to scale up production and revenues in late 2022 through 2023.

If Humacyte is able to meet expectations then this stock has enormous upside — I just don’t expect it to be an overnight success so you should have plenty of time to start a position assuming you’re willing to be patient and bet on the long term.